Skip to main content
Premium Trial:

Request an Annual Quote

Canon Shareholders Say Firm Can Begin Making, Selling Microarrays

NEW YORK, March 30 (GenomeWeb News) - Canon may soon enter the microarray market.

 

Shareholders of the electronics giant today approved an amendment to the firm's articles of incorporation that will allow Canon to move forward with its plans to produce and commercialize its own line of microarrays.

 

The move represents a new step forward for the company, which has been racking up array-related IP in the US and toying with the idea of entering the market with budget microarrays produced with its Bubble Jet printing technology.

 

Still, Canon made similar public gestures towards entering the market in 2001 and 2003, and has yet to back up its talk with product.

 

Following the approval, Canon spokesperson Richard Berger told IDG News Service in Tokyo that the company has yet to decide when and how it will launch its new product. The same news service reported that Canon has been providing chips for a research project paid for by the Japanese government in colon cancer.

 

The participants of the annual shareholders' meeting in Tokyo have added a platform to the company's charter that now allows the "production and sale of pharmaceutical products," under which microarrays are covered as a legitimate part of the firm's business.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.